BridgeBio Pharma Inc

BBIO is deeply oversold around its 200 DMA support after a sharp downtrend, and mean-reversion eligibility forces a medium-term bullish bias. Short-term price extension below declining EMAs at extreme OS levels suggests a tactical entry opportunity as price stabilizes near support, warranting a Buy Now execution on a pullback into this major structural zone.

• ↑Phase 3 acoramidis trial shows reversal of cardiac changes in ATTR-CM
• ↑Infigratinib Phase 3 PROPEL 3 trial positive in achondroplasia, NDA filing planned
• ↓Negative earnings yield and low book-to-price signal possible overvaluation